Achieve Life Sciences

Achieve Life Sciences

Pharmaceuticals
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.

$717.2M

Market Cap • 10/15/2026

1991

(35 years)

Founded

1995

(31 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

—

P/S

—

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

—

EPS

—

Market Cap

Market Cap

717,2M

EV

544,9M

EV/Revenue

0

EV/EBITDA

-9,4

EV/EBIT

-9,3

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-24,2%

Total Yield

-24,2%

Payout

0%

Retained Earnings

-345,2M

Profitability

Gross Margin

—

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

0%

Capex/Revenue

0%

Capex/D&A

8,4%

Capex/OCF

0%

SBC/OCF

—

% PPE

0%

% Goodwill

0,5%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

16%

CAGR Net Income 5Y

32,6%

CAGR EPS 5Y

-21,1%

CAGR OCF 5Y

16%

Leverage

N.D./EBITDA

3

Debt/Equity

0%

Current Ratio

1

Quick Ratio

0,9

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium